NeoGenomics, Inc. (NEO) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $10.69 (-3.74%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| May 6, 2025 | David Westenberg | Piper Sandler | $12.00 | +12.3% |
| Jan 11, 2025 | Mark Massaro | BTIG | $18.00 | +68.4% |
| Jul 30, 2024 | Mike Matson | Needham | $19.00 | +77.7% |
| May 2, 2024 | Mark Massaro | BTIG | $21.00 | +96.4% |
| Aug 21, 2023 | Mason Carrico | Stephens | $18.00 | +68.4% |
| Aug 17, 2022 | David Westenberg | Piper Sandler | $19.00 | +77.7% |
| Jun 3, 2021 | Matthew Sykes | Goldman Sachs | $55.00 | +414.5% |
| May 25, 2021 | Sandy Draper | Guggenheim | $54.00 | +405.1% |
Top Analysts Covering NEO
NEO vs Sector & Market
| Metric | NEO | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.40 |
| Analyst Count | 6 | 8 | 19 |
| Target Upside | +70.9% | +11475.0% | +17.1% |
| P/E Ratio | -2.15 | 3.91 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $795M | $797M | $797M | 9 |
| 2027-03-31 | $203M | $204M | $206M | 4 |
| 2027-06-30 | $215M | $216M | $218M | 6 |
| 2027-09-30 | $224M | $225M | $227M | 4 |
| 2027-12-31 | $229M | $230M | $232M | 7 |
| 2028-03-31 | $219M | $220M | $222M | 3 |
| 2028-06-30 | $238M | $239M | $241M | 5 |
| 2028-09-30 | $247M | $248M | $250M | 3 |
| 2028-12-31 | $250M | $251M | $254M | 6 |
| 2029-12-31 | $1.02B | $1.03B | $1.03B | 3 |
| 2030-12-31 | $1.10B | $1.11B | $1.11B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.11 | $0.17 | $0.22 | 7 |
| 2027-03-31 | $0.06 | $0.06 | $0.06 | 2 |
| 2027-06-30 | $0.08 | $0.08 | $0.08 | 2 |
| 2027-09-30 | $0.09 | $0.09 | $0.09 | 2 |
| 2027-12-31 | $0.11 | $0.11 | $0.11 | 2 |
| 2028-03-31 | $0.06 | $0.06 | $0.06 | 3 |
| 2028-06-30 | $0.09 | $0.09 | $0.09 | 3 |
| 2028-09-30 | $0.14 | $0.14 | $0.14 | 3 |
| 2028-12-31 | $0.19 | $0.19 | $0.19 | 3 |
| 2029-12-31 | $0.62 | $0.62 | $0.62 | 1 |
| 2030-12-31 | $0.80 | $0.81 | $0.82 | 1 |
Frequently Asked Questions
What is the analyst consensus for NEO?
The consensus among 6 analysts covering NeoGenomics, Inc. (NEO) is Buy with an average price target of $19.00.
What is the highest price target for NEO?
The highest price target for NEO is $55.00, set by Matthew Sykes at Goldman Sachs on 2021-06-03.
What is the lowest price target for NEO?
The lowest price target for NEO is $12.00, set by David Westenberg at Piper Sandler on 2025-05-06.
How many analysts cover NEO?
6 analysts have issued ratings for NeoGenomics, Inc. in the past 12 months.
Is NEO a buy or sell right now?
Based on 6 analyst ratings, NEO has a consensus rating of Buy (2.00/5) with a +70.9% upside to the consensus target of $19.00.
What are the earnings estimates for NEO?
Analysts estimate NEO will report EPS of $0.17 for the period ending 2026-12-31, with revenue estimated at $797M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.